245 related articles for article (PubMed ID: 23404426)
1. Inhibition of proliferation of estrogen receptor‑positive MCF‑7 human breast cancer cells by tamoxifen through c‑Jun transcription factors.
Xu Y; Zou ST; Zhu R; Li W; Gu CW; Wei SH; Xie JM; Wu HR
Mol Med Rep; 2013 Apr; 7(4):1283-7. PubMed ID: 23404426
[TBL] [Abstract][Full Text] [Related]
2. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.
Johnston SR; Lu B; Scott GK; Kushner PJ; Smith IE; Dowsett M; Benz CC
Clin Cancer Res; 1999 Feb; 5(2):251-6. PubMed ID: 10037172
[TBL] [Abstract][Full Text] [Related]
3. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
4. cFos is critical for MCF-7 breast cancer cell growth.
Lu C; Shen Q; DuPré E; Kim H; Hilsenbeck S; Brown PH
Oncogene; 2005 Sep; 24(43):6516-24. PubMed ID: 16027729
[TBL] [Abstract][Full Text] [Related]
5. Activation and inhibition of the AP-1 complex in human breast cancer cells.
Chen TK; Smith LM; Gebhardt DK; Birrer MJ; Brown PH
Mol Carcinog; 1996 Mar; 15(3):215-26. PubMed ID: 8597534
[TBL] [Abstract][Full Text] [Related]
6. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
[TBL] [Abstract][Full Text] [Related]
7. cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype.
Smith LM; Wise SC; Hendricks DT; Sabichi AL; Bos T; Reddy P; Brown PH; Birrer MJ
Oncogene; 1999 Oct; 18(44):6063-70. PubMed ID: 10557095
[TBL] [Abstract][Full Text] [Related]
8. Cyclooxygenase-2 utilizes Jun N-terminal kinases to induce invasion, but not tamoxifen resistance, in MCF-7 breast cancer cells.
Gonzalez-Villasana V; Gutiérrez-Puente Y; Tari AM
Oncol Rep; 2013 Sep; 30(3):1506-10. PubMed ID: 23783392
[TBL] [Abstract][Full Text] [Related]
9. Induction of methionine adenosyltransferase 2A in tamoxifen-resistant breast cancer cells.
Phuong NT; Kim SK; Im JH; Yang JW; Choi MC; Lim SC; Lee KY; Kim YM; Yoon JH; Kang KW
Oncotarget; 2016 Mar; 7(12):13902-16. PubMed ID: 26418898
[TBL] [Abstract][Full Text] [Related]
10. Involvement of activator protein-1 (AP-1) in induction of apoptosis by vitamin E succinate in human breast cancer cells.
Zhao B; Yu W; Qian M; Simmons-Menchaca M; Brown P; Birrer MJ; Sanders BG; Kline K
Mol Carcinog; 1997 Jul; 19(3):180-90. PubMed ID: 9254885
[TBL] [Abstract][Full Text] [Related]
11. Induction of retinoid resistance in breast cancer cells by overexpression of cJun.
Yang L; Kim HT; Munoz-Medellin D; Reddy P; Brown PH
Cancer Res; 1997 Oct; 57(20):4652-61. PubMed ID: 9377582
[TBL] [Abstract][Full Text] [Related]
12. Estrogen receptor-α variant, ER-α36, is involved in tamoxifen resistance and estrogen hypersensitivity.
Zhang X; Wang ZY
Endocrinology; 2013 Jun; 154(6):1990-8. PubMed ID: 23546601
[TBL] [Abstract][Full Text] [Related]
13. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
Osipo C; Gajdos C; Cheng D; Jordan VC
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
[TBL] [Abstract][Full Text] [Related]
14. Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells.
Frankel LB; Lykkesfeldt AE; Hansen JB; Stenvang J
Breast Cancer Res Treat; 2007 Aug; 104(2):165-79. PubMed ID: 17061041
[TBL] [Abstract][Full Text] [Related]
15. Role of PKC-ERK signaling in tamoxifen-induced apoptosis and tamoxifen resistance in human breast cancer cells.
Li Z; Wang N; Fang J; Huang J; Tian F; Li C; Xie F
Oncol Rep; 2012 Jun; 27(6):1879-86. PubMed ID: 22427054
[TBL] [Abstract][Full Text] [Related]
16. The role of captopril and losartan in prevention and regression of tamoxifen-induced resistance of breast cancer cell line MCF-7: an in vitro study.
Namazi S; Rostami-Yalmeh J; Sahebi E; Jaberipour M; Razmkhah M; Hosseini A
Biomed Pharmacother; 2014 Jun; 68(5):565-71. PubMed ID: 24975086
[TBL] [Abstract][Full Text] [Related]
17. A naringenin-tamoxifen combination impairs cell proliferation and survival of MCF-7 breast cancer cells.
Hatkevich T; Ramos J; Santos-Sanchez I; Patel YM
Exp Cell Res; 2014 Oct; 327(2):331-9. PubMed ID: 24881818
[TBL] [Abstract][Full Text] [Related]
18. AP-1 blockade inhibits the growth of normal and malignant breast cells.
Ludes-Meyers JH; Liu Y; Muñoz-Medellin D; Hilsenbeck SG; Brown PH
Oncogene; 2001 May; 20(22):2771-80. PubMed ID: 11420689
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen-induced activation of p21Waf1/Cip1 gene transcription is mediated by Early Growth Response-1 protein through the JNK and p38 MAP kinase/Elk-1 cascades in MDA-MB-361 breast carcinoma cells.
Kim CG; Choi BH; Son SW; Yi SJ; Shin SY; Lee YH
Cell Signal; 2007 Jun; 19(6):1290-300. PubMed ID: 17307334
[TBL] [Abstract][Full Text] [Related]
20. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
